Ovarian Cancer Identification on CT Using Deep Learning

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age20+
SponsorChang Gung Memorial Hospital

About this trial

Ovarian cancer remains the deadliest gynecologic malignancy, with poor survival rates largely due to late-stage diagnosis. Early detection is crucial, yet no universally accepted screening method exists. Current imaging techniques and biomarkers, such as CA-125, have limitations in specificity and sensitivity. This study aims to develop and evaluate a deep learning-based computer-aided diagnosis tool (CAT-OV), for ovarian cancer detection using CT imaging. The system integrates a Body Part Regression (BPR) model for pelvic localization and a Multiple Instance Learning (MIL) ensemble classifier for cancer prediction. The model was trained and validated using retrospective datasets from Taiwan, the United States, and a nationwide real-world cohort. Stringent preprocessing and quality control measures were implemented to enhance model accuracy. Results highlight the potential of AI-driven CT screening in improving early detection, though further validation is needed for clinical adoption.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Age ≥ 20 years old.

Female

undergone a CT scan

undergone a CT scan within 180 days prior to ovarian surgery for histopathological evaluation.

Disqualifiers

Age < 20 years old.

Non-female

Non-CT imaging

Incorrect image orientation

Trial population

Women who have undergone a CT scan.

Trial design

Design model

Case-control

Time perspective

Retrospective

Treatments tested in this trial

Not listed

Trial groups

12,578 Participants
are grouped into 2 trial groups
Group A: control group
Group B: case group

Trial outcomes

Primary outcomes

1

Performance of a deep learning-based computer-aided diagnosis tool (CAT-OV) for identification of primary ovarian cancer on CT

Sensitivity, Specificity, Accuracy, PPV, NPV, AUC

Time frame
Perioperative/Periprocedural 180 days

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.